Effective delivery of endogenous antioxidants ameliorates diabetic nephropathy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Park, Yongsoo ^a   Kim, Hyunok ^a   Park, Leejin ^a   Min, Dongsoo ^a   Park, Jinseu ^b   Choi, Sooyoung ^b   Park, Moon Hyang ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN II; ANTIOXIDANT; MESSENGER RNA; METALLOTHIONEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAT METALLOTHIONEIN FUSION PROTEIN; TAT SUPEROXIDE DISMUTASE FUSION PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; PEPTIDE; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GLOMERULUS; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; LONG EVANS RAT; METABOLISM; PATHOLOGY;

ANIMALIA; RATTUS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FREE RADICAL SCAVENGERS; MALE; MESANGIAL CELLS; METALLOTHIONEIN; PEPTIDES; RATS; RATS, LONG-EVANS; SUPEROXIDE DISMUTASE;

EID: 84938365272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130815     Document Type: Article

References (30)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28(1):164-176, 2005
2. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127-1133, 1999
3. Chandel NS, Budinger GR. The cellular basis for diverse responses to oxygen. Free Radic Biol Med 42:165-174, 2007
4. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106(2):26-31, 2007
5. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 14:S250-253, 2003
6. Noh H, Ha H. Reactive oxygen species and oxidative stress. Contrib Nephrol 170:102-112, 2011
7. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18:2439-2446, 2007
8. Tan AL, Forbes JM, Cooper ME. AGE, RAGE and ROS in diabetic nephropathy. Semin Nephrol 27:130-143, 2007
9. Mankhey RW, Wells CC, Bhatti F, Maric C. 17 beta-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 292 (2):769-777, 2007
10. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 27:195-207, 2007
11. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358-1373, 2003
12. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16:703-711, 2005
13. Park L, Min D, Kim H, Chung HY, Lee CH, Park IS, et al. TAT-enhanced delivery of metallothionein can partially prevent the development of diabetes. Free Radic Biol Med 51(9):1666-1674, 2011
14. Min D, Kim H, Park L, Kim T, Hwang S, Kim M, et al. Amelioration of diabetic neuropathy by TAT-mediated enhanced delivery of metallothionein and SOD. Endocrinology 153(1):81-91, 2012
15. Park L, Min D, Kim H, Park J, Choi S, Park Y. The combination of metallothionein and superoxide dismutase protects pancreatic β cells from oxidative damage. Diabetes Metab Res Rev 27(8):802-808, 2011
16. Becker-Hepak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 24: 247-256, 2001
17. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572, 1999
18. Johnson RM, Harrison SD, Maclean D. Therapeutic applications of cell-penetrating peptides. Methods Mol Biol 683:535-551, 2011
19. Song CY, Kim BC, Lee HS. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells. Transl Res 151(1):27-35, 2008
20. Kanwar YS, Sun L, Xie P, Liu F, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol Mech Dis 6:395-423, 2011
21. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107(9):1058-1070, 2010
22. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 59:415-424, 2001
23. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-κβ activation in the late diabetic complications. Biofactors 10: 157-167, 1999
24. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose induced nuclear factor-κβ activation in monocyte chemo attractant protein-1 expression by Mesangial cells. J Am Soc Nephrol 13: 894-902, 2002
25. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the nuclear factor kappaB p65 subunit. Biochem Pharmacol 64: 963-970, 2002
26. Joseph LE, Ira DG, Betty AM, Gerold MG. Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes. Endocr Rev 23(5):599-622, 2002
27. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292(2): F617-627, 2007
28. Zhou T, He X, Cheng R, Zhang B, Zhang RR, Chen Y, et al. Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia 55 (1):255-266, 2012
29. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847, 2002
30. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54(6):1626-1634, 2005